408
W. Zhou et al. / Dyes and Pigments 91 (2011) 404e412
2.4.9. 3-Hexylthiophene-2-carbaldehyde (3-a)
purple solid of compound Z3 was obtained (0.08 g, 26%). FT-IR
(KBr, vmax/cmꢂ1): 2959, 2927, 2851, 2347, 2216, 1622, 1449,
1384, 1068, 979, 793, 784. UVevis lmax (CHCl3)/nm: 432, 558. 1H
Dried magnesium pieces (0.4 g, 17 mmol) were placed into a dry
100 mL three-necked round-bottomed flask together with a few
small crystals of iodine. THF (10 mL) was added sequentially under Ar
atmosphere, and then a THF solution of 2-bromo-3-hexylthiophene
(4.41 g, 15 mmol) was dropped slowly at 60e70 ꢀC. After 6 h, the
reaction mixture was cooled down to ꢂ40 ꢀC and 6 mL DMF was
added. The reaction was allowed to progress for a further 20 h
after warming to room temperature. At last, 10 mL diluent hydro-
chloric acid was added into it. The solution was extracted
with dichloromethane, and washed with H2O. The organic layer was
dried over anhydrous MgSO4. Solvent was removed by rotary evap-
oration, and the residue was purified by silica gel column chroma-
tography with petroleum ether/dichloromethane (5/1) as eluent to
yield 3-a as a buff liquid (1.5 g, 50%). 1H NMR (CDCl3, 400 MHz,
NMR (CDCl3, 400 MHz, d/ppm): 9.25e8.93 (m, 8 H, pyrrolic-H),
8.60 (s, 1 H, vinyl-H), 8.21 (s, 1 H, TheH), 7.70e7.69 (s, 3 H,
TheH), 7.17 (s, 3 H, TheH), 2.84 (s, 9 H, eCH3), 2.52e2.49 (t, 2
H, eCH2), 1.47e1.27 (m, 4 H, eCH2), 0.93e0.80 (m, 4 H, eCH2),
0.51e0.47 (t, 3 H, eCH3). 13C NMR (DMSO, 100 MHz,
d/ppm): 151.1,
150.9, 150.8, 150.5, 145.9, 142.1, 142.1, 141.0, 140.9, 133.8, 133.2,
131.6, 132.3, 132.2, 132.1, 131.5, 130.5, 125.3, 125.0, 123.6, 113.7,
113.3, 110.0, 29.7, 29.3, 28.9, 28.3, 22.0, 20.8, 15.5, 13.9. MAL-
DIeTOF MS (C49H39N5O2S4Zn) m/z : calcd for 921.12; found
921.23.
2.4.14. 5-(3,4-Ethylenedioxyl)thienyl-10,15,20-tris(5-methylthien-
2-yl)porphyrin (4-b)
d/ppm): 10.05 (s, 1 H, eCHO), 7.66e7.64 (d, 1 H, TheH), 7.02e7.01
(d, 1 H, TheH), 2.99e2.96 (t, 2 H, eCH2), 1.71e1.64 (m, 4 H, eCH2),
The synthetic procedure for 4-b was similar to that for 1-b,
except that 4-a (2.88 g, 17 mmol) was used instead of
1.38e1.27 (m, 4 H, eCH2), 0.91e0.88 (t, 3 H, eCH3). 13C NMR (CDCl3,
100 MHz,
28.5, 22.5, 13.9.
d
/ppm): 182.1, 152.7, 137.7, 134.3, 130.6, 31.5, 31.3, 28.9,
2-thiophenealdehyde.
A
purple solid of compound 4-b was
/ppm): 9.15e9.11
obtained (1.2 g, 9.6%). 1H NMR (CDCl3, 400 MHz,
d
(m, 8 H, pyrrolic-H), 7.69e7.68 (d, 3 H, TheH), 7.17 (d, 3 H, TheH),
6.93 (s, 1 H, TheH), 4.45 (t, 2 H, eOCH2), 4.28 (t, 2 H, eOCH2), 2.84
(s, 9 H, eCH3), ꢂ2.58 (s, 2 H, eNH). 13C NMR (CDCl3, 100 MHz,
2.4.10. 5-(3-Hexylthien-2-yl)-10,15,20-tris(5-methylthien-2-yl)
porphyrin (3-b)
The synthetic procedure for 3-b was similar to that for 2-b, except
that 3-a (1.88 g,17 mmol) was used instead of 2-thiophenealdehyde.
A purple solid of compound 3-b was obtained (1.0 g, 7%). 1H NMR
d/ppm): 142.5, 140.5, 140.3, 133.8, 133.7, 131.0, 129.0, 128.2, 125.3,
124.5, 117.0, 113.2, 112.7, 108.7, 101.3, 64.8, 15.5. MALDI-TOF MS
(C41H30N4O2S4) m/z: calcd for 739.12; found 739.19.
(CDCl3, 400 MHz, d/ppm): 9.12e8.90 (m, 8 H, pyrrolic-H), 7.75e7.74
(t,1 H, TheH), 7.69 (d, 3 H, TheH), 7.39e7.37 (t,1 H, TheH), 7.17 (s, 3 H,
TheH), 2.84e2.75 (s, 9 H, eCH3), 2.49e2.45(t, 2 H, eCH2), 1.45
(t, 2 H, eCH2),1.28 (t, 2 H, eCH2), 0.94e0.81 (m, 4 H, eCH2), 0.54e0.51
2.4.15. 5-[5-(3,4-Ethylenedioxyl-5-formyl)thienyl-10,15,20-tris(5-
methylthien-2-yl) porphyrin (4-c)
The synthetic procedure for 4-c was similar to that for 1-c,
except that 4-b (0.60 g, 0.81 mmol) was used instead of 2-b. A
purple solid of compound 4-c was obtained (0.30 g, 48.3%). 1H
(t, 3 H, eCH3), ꢂ2.60 (s, 2 H, eNH).13C NMR (CDCl3,100 MHz,
d/ppm):
145.8, 142.5, 140.2, 133.8, 133.7, 127.2, 125.6, 124.5, 113.0, 112.7, 111.1,
31.2, 30.3, 29.3, 28.7, 22.7, 22.2, 14.1. MALDI-TOF MS (C45H40N4S4)
m/z: calcd for 765.21; found 765.30.
NMR (CDCl3, 400 MHz, d/ppm): 10.30 (s, 1 H, eCHO), 9.16e9.05 (m,
8 H, pyrrolic-H), 7.70 (d, 3 H, TheH), 7.17 (d, 3 H, TheH), 4.60 (t, 2
H, eOCH2), 4.33 (t, 2 H, eOCH2), 2.84 (s, 9 H, eCH3), ꢂ2.60 (s, 2
2.4.11. 5-(3-Hexyl-5-formylthien-2-yl)-10,15,20-tris (5-
methylthien-2-yl)porphyrin (3-c)
The synthetic procedure for 3-c was similar to that for 1-c, except
that 3-b (0.5 g, 0.58 mmol) was used instead of 2-b. A purple solid of
compound 3-c was obtained (0.21 g, 40.7%). 1H NMR (CDCl3,
H, eNH). 13C NMR (CDCl3, 100 MHz,
d/ppm): 180.0, 147.2, 142.7,
140.1, 140.0, 133.9, 128.5, 124.6, 119.6, 114.0, 113.2, 106.2, 65.5, 64.6,
15.5. MALDI-TOF MS (C42H30N4O3S4) m/z: calcd for 767.12; found
767.26.
400 MHz,
d
/ppm): 10.21 (s, 1 H, eCHO), 9.11e8.80 (m, 8 H, pyrrolic-
2.4.16. 5-[5-(3,4-Ethylenedioxyl-5-formyl)thienyl-10,15,20-tris(5-
methylthien-2-yl) porphyrin zine (4-d)
The synthetic procedure for 4-d was similar to that for 1-d,
except that 4-c (0.3 g, 0.39 mmol) was used instead of 1-c. A
purple solid of compound 4-d was obtained (0.31 g, 95%). 1H
H), 8.06 (d, 1 H, TheH), 7.68 (d, 3 H, TheH), 7.16 (d, 3 H, TheH), 2.82
(s, 9 H, eCH3) 2.45e2.42 (t, 2 H, eCH2),1.45e1.42 (m, 2 H, eCH2),1.25
(m, 2 H, eCH2), 0.92e0.80 (m, 4 H, eCH2), 0.52e0.49 (m, 3
H, eCH3), ꢂ2.61 (s, 2 H, eNH). 13C NMR (CDCl3, 100 MHz,
d/ppm):
183.2,148.0,147.5,143.3,142.7,140.2,140.0,136.0,133.9,124.6,113.8,
113.2, 108.8, 31.1, 30.0, 29.7, 28.6, 22.2, 21.5, 15.5, 13.7. MALDIeTOF
MS (C46H40N4OS4) m/z: calcd for 793.20; found 793.28.
NMR (CDCl3, 400 MHz, d/ppm): 10.31 (s, 1 H, eCHO), 9.15e9.02
(m, 8 H, pyrrolic-H), 7.71 (d, 3 H, TheH), 7.17 (d, 3 H, TheH), 4.60
(t, 2 H, eOCH2), 4.33 (t, 2 H, eOCH2), 2.84 (s, 9 H, eCH3). MAL-
DIeTOF MS (C42H28N4O3S4Zn) m/z: calcd for 829.05; found
829.11.
2.4.12. 5-(3-Hexyl-5-formylthien-2-yl)-10,15,20-tris(5-
methylthien-2-yl)porphyrin zine (3-d)
The synthetic procedure for 3-d was similar to that for 1-d,
except that 3-c (0.21 g, 0.24 mmol) was used instead of 1-c. A
purple solid of compound 3-d was obtained (0.20 g, 90%). 1H NMR
2.4.17. 2-Cyano-3-(3,4-ethylenedioxyl-5-(10,15,20-tris(5-
methylthien-2-yl)) porphyrinatozinc(II)yl)thienyl acrylic acid (Z4)
The synthetic procedure for Z4 was similar to that for Z1,
except that 4-d (0.20 g, 0.24 mmol) was used instead of 1-d. A
purple solid of compound Z4 was obtained (0.12 g, 56.1%). FT-IR
(KBr, vmax/cmꢂ1): 2966, 2843, 2364, 2206, 1611, 1579, 1441, 1383,
1319, 1261, 1015, 1071, 799, 712. UVevis lmax (CHCl3)/nm: 435,
(CDCl3, 400 MHz, d/ppm): 10.21 (s, 1 H, eCHO), 9.11e8.83 (m, 8 H,
pyrrolic-H), 8.07 (d, 1 H, TheH), 7.67 (d, 3 H, TheH), 7.16 (d, 3 H,
TheH), 2.82(s, 9 H, eCH3) 2.45e2.42(t, 2 H, eCH2), 1.45e1.42 (m,
2 H, eCH2), 1.25 (m, 2 H, eCH2), 0.92e0.80 (m, 4 H, eCH2),
0.52e0.49 (m, 3 H, eCH3). MALDIeTOF MS (C46H38N4OS4Zn) m/z:
calcd for 855.15; found 855.21.
562. 1H NMR (DMSO, 400 MHz,
d/ppm): 9.16e9.06 (m, 8 H,
pyrrolic-H), 8.51 (s, 1 H, vinyl-H), 7.72 (d, 3 H, TheH), 7.27 (d, 3 H,
TheH), 4.65 (t, 2 H, eOCH2). 4.37 (t, 2 H, eOCH2), 2.78 (s, 9
2.4.13. 2-Cyano-3-(4-hexyl-5-(10,15,20-tris(5-methylthien-2-yl))
porphyrinatozinc(II)yl)thienyl acrylic acid (Z3)
The synthetic procedure for Z3 was similar to that for Z1,
except that 3-d (0.20 g, 0.21 mmol) was used instead of 1-d. A
H, eCH3). 13C NMR (DMSO, 100 MHz,
d/ppm): 151.1, 150.9, 150.8,
150.4, 142.2, 141.0, 133.9, 132.3, 132.1, 131.9, 125.4, 113.3, 22.9, 15.5.
MALDIeTOF MS (C45H29N5O4S4Zn) m/z: calcd for 895.04; found
895.12.